Completed PHASE3 NCT00779402

PROvenge Treatment and Early Cancer Treatment

Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial

Sponsor: Dendreon

Conditions Prostate Cancer

Interventions Control Sipuleucel-T

Updated 7 times since 2017 Last updated: Jun 29, 2017 Started: Oct 31, 2001 Primary completion: Aug 31, 2006 Completion: May 31, 2015

Listed as NCT00779402, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by Dendreon, it has been updated 7 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2018 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dendreon

Data source: Dendreon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Berkeley, United States , Bryn Mawr, United States , Charlotte, United States , Columbus, United States , Laguna Hills, United States , Memphis, United States , New York, United States , Park Ridge, United States , Philadelphia, United States and 6 more locations